Operator

Welcome to XVIVO Q1 Report for 2026. [Operator Instructions] Now I will hand the conference over to CEO, Christoffer Rosenblad; and CFO, Kristoffer Nordstrom. Please go ahead.

Christoffer Rosenblad
Chief Executive Officer

Thank you so much. Good morning and good afternoon, everyone, and welcome to XVIVO's earnings call for the first quarter of 2026. We can go to Slide #2 and just -- today's presenters are me, Christoffer Rosenblad calling in from the 2026 ISHLT Conference in Toronto, Canada; and Kristoffer Nordstrom, CFO calling in from Philadelphia in the United States. And with that, we can go to Slide #3, financial at the glance. So we see that the first quarter of this year showed a 23% organic top line growth. This is equivalent to an 18% organic top line growth if we adjust for the U.S. CAP trial revenue compared to the same quarter last year.

EBITDA was kept at a healthy level, resulting in a positive cash flow for the second consecutive quarter. The CFO, Kristoffer Nordstrom will get more into the details on sales, gross margin and EBITDA later in this presentation. Short on the segments. Both the thoracic and abdominal segment are growing rapidly in both regions, which are North America and Europe. The lung market trend we saw in Q4 last year